Moderna’s stock jumped over 7% after the US Food and Drug Administration agreed to review its flu vaccine, reversing an earlier decision. The news lifted shares by nearly 4% in afternoon trades. This move comes after the company reported strong fourth-quarter sales last week.
Source: https://www.investors.com/news/technology/moderna-stock-mrna-fda-flu-vaccine-reversal